Multiple, poorly defined immune and structural cell components

Multiple, poorly defined immune and structural cell components is a descriptive category rather than a specific, validated therapeutic target. This terminology is typically used when a therapeutic agent's precise mechanism of action is not fully understood or when it exerts pleiotropic effects across a wide array of cellular environments (Swinney & Anthony, 2011, Nature Reviews Drug Discovery). In such instances, the drug may interact with various immune cells, such as lymphocytes or myeloid cells, and structural components, such as extracellular matrix proteins or fibroblasts, without a primary, high-affinity binding site (Moffat et al., 2017, Nature Reviews Drug Discovery). This lack of definition is common in phenotypic drug discovery, where compounds are identified based on their ability to alter a disease-relevant phenotype in a cell-based or animal model (Eder et al., 2014, Nature Reviews Drug Discovery). While this approach can lead to the discovery of first-in-class medicines, it presents significant challenges in optimizing potency and predicting safety profiles. Without a defined target, it is difficult to develop specific biomarkers for patient stratification or to monitor target engagement during clinical trials (Zheng et al., 2013, Current Protocols in Chemical Biology).

Other names

Undefined cellular componentsNon-specific immune and structural targetsPhenotypic targetsPoorly characterized biological components

The mechanism of action involves non-specific modulation of multiple cellular pathways and structural elements, lacking a defined primary molecular target (Swinney & Anthony, 2011, Nature Reviews Drug Discovery).